BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Based on these results, we have demonstrated that co-administration of BCR::ABL1 inhibitors with recently developed FLT3 inhibitors, or single treatment with ponatinib, a third generation BCR::ABL1 TKI that targets BCR::ABL1 and FLT3 simultaneously, suppressed FLT3-TAZ signaling pathway, restored TKI sensitivity, and promoted cell death in drug resistant FLT3+ BP-CML cells.